The State Medical Insurance Bureau named Into Credit Enterprise, and the credit evaluation system played a greater role

On August 4, the National Medical Insurance Bureau released the "Severe" and "Especially serious" dishonesty assessment results (No. 3). From June 1st to June 30, 2022, the provinces rated the provinces as "particularly serious" and "severe" the situation of "serious" medical companies for publicity. Yunnan Tongfeng Pharmaceutical Co., Ltd. and Ningxia Minning Pharmaceutical Co., Ltd. are rated as "serious" dishonesty level.

Medical prices and recruitment credit evaluation systems are the basic system of centralized procurement markets for drugs and medical consumables. It is of great significance to regulate market behavior, purify the trading environment, and protect the interests of the masses. In August 2020, the National Medical Insurance Bureau issued the "Guiding Opinions on Establishing a Medical Price and Recruitment Credit Evaluation System", proposed to establish a list of credit evaluation catalogs, implement the active commitment system of pharmaceutical companies, establish a channel for recording of credit information reports, and develop medical enterprise credit credit. 6 items such as rating. Since the implementation of the system, it has formulated prices for guiding and regulating the centralized procurement market for pharmaceutical products and promoting pharmaceutical companies in accordance with the principle of "fairness, reasonableness, and honesty, and quality and price.

Credit evaluation has landed nationwide

Progressive progress has been achieved in some regions

The "Guiding Opinions on the Establishment of Medicine Price and Recruitment Credit Evaluation System" requires that provincial -provincial and medical centralized procurement agencies are required to comprehensively establish a medical price and recruitment credit evaluation system. According to statistics from the National Medical Insurance Bureau's pharmaceutical price and bidding procurement guidance center, as of January 2021, all provinces, autonomous regions, municipalities, and Xinjiang Production and Construction Corps have all formulated specific policies to implement the credit evaluation system, publicized the list of credit items and credit evaluation operations Specifications and tailoring benchmarks.

After the establishment of a credit evaluation system for the price recruitment, the State Medical Insurance Bureau has promoted the implementation of integrated institutions at all levels in a timely manner. In accordance with the principles of territory, centralized procurement institutions are required to pay close attention to the decision of referee documents and administrative penalties publicly publicly publicized by courts, taxation, and market supervision departments in the regional courts, especially the typical cases reported by the media centralized reports. Get substantial governance results in credit rating and hierarchical disposal as soon as possible.

The first national credit evaluation of the governance of the "serious" level of governance occurred in Zhejiang Province in April 2021, marking that the price recruitment credit evaluation system has entered a new stage of exerting substantial effects. In this case, the Luguyan peptide injection of Harbin Yuheng Pharmaceutical Co., Ltd. has a commercial bribery behavior given to the deduction in Zhejiang Province. "Severe" and was suspended from the company's Lugua polypeptide injection in Zhejiang Province.

At present, all provinces have conducted credit evaluations on companies that have dishonesty in the area of ​​the area in accordance with the price of the province in accordance with the price of the province, and make a written reminder, restricting or suspending related product hanging or procurement in accordance with the regulations, etc. Essence Some pharmaceutical companies have also adopted measures such as active price cuts to repair credit.

Pharmaceutical business bribery and collection and breaking supply are the "severe disaster areas" in the disaster

The "Price Recruitment Credit Evaluation" column of the National Medical Insurance Bureau announced "serious" and "particularly serious" companies that broke their trust in order to strengthen social supervision and increase warning. As of now, the National Medical Insurance Administration has issued a three -phase price recruitment credit evaluation "serious" and "particularly serious" dishonesty assessment results report, involving 13 companies.

Note 1: Sichuan Zhitong Pharmaceutical Co., Ltd. has given recovery or improper interests at the former Aba Prefecture People's Hospital and the former Aba Prefecture Tibetan Hospital, involving the amount of 450,000 yuan and 710,000 yuan, respectively.

According to the "Pharmaceutical Price and Recruitment Trust Item List (2020 Edition)" issued by the State Medical Insurance Bureau, the dishonesty of the list of directory lists mainly includes giving rebates or other improper benefits in pharmaceutical purchase and sale (referred to as "medical commercial bribery") , Taxation illegal, the implementation of monopoly behaviors, improper price behaviors, disturbing centralized procurement order, malicious violations of contracts, etc. are contrary to honesty and trustworthy. Judging from the "severe" and "particularly serious" broom companies released by the State Medical Insurance Bureau, pharmaceutical commercial bribery and collection of contracts violated the contract is the "hardest hit area" for the current bidding and purchasing dishonesty. The former is the focus of correction in the field of medical purchase and sales. In the past two years, it has attracted much attention from social and related departments; the latter has a significant impact on the implementation effect of the collection of collection and land. Focus on behaviors that strive for avoidance.

National Cai introduced credit evaluation

The seventh batch of collecting collection affects the selection of supply areas

In order to effectively restrain the performance of enterprises' bribery and out of stock, the centralized procurement of drugs in the national organization has gradually introduced the price recruitment and credit evaluation mechanism, and the credit evaluation results are associated with product declaration qualifications, election rankings, and market allocation results. Credit evaluation is effectively constrained with corporate interests.

The fifth batch of national concentrated band quantity procurement was first quoted the credit evaluation system. First of all, adding "not being included in the current" National Pharmaceutical Price and Recruitment of Risk Warning List "in the qualifications of the application for enterprises; secondly At the same time, companies that have not been rated by any province based on medical prices and recruitment credit evaluation systems as "medium", "serious" or "particularly serious" enterprises priority; third, it is clear The recruitment credit evaluation system is rated as "serious" or "particularly serious" level of dishonesty ", and the province can reject the selected enterprise. The seventh batch of national centralized batch of national batch of national batch of national batch of nationally increases the credit. The application intensity and intensity of the evaluation system. If the proposed enterprise is appraised by any province, it is rated as "severe" or "particularly serious" dishonesty level based on the evaluation of the medical price and recruitment credit evaluation system, or the company to be selected in the country within two years is in the country in the country in the country. If the selection varieties in the centralized procurement of drugs are disqualified by the joint procurement office, they do not have the qualifications for the first time to confirm the region in the main region and preparation area, that is, a relatively few supply areas.

Jiang Changsong, director of the Medical Price and Tendering Purchasing Research Office of the National Medical Security Research Institute of the Capital Medical University, believes that in the future, the credit evaluation and performance will be integrated into the main links of the collection and continuation rules, so that they will be qualified for corporate declarations, comprehensive scores, and comprehensive scores. Election qualifications, election positions, and supply areas to play a substantial role in the selection of supply areas. For example, in the previous round of selected companies, such as the results of the comprehensive evaluation or credit, and the performance of the contract, they can be given priority in the continuation work; if the credit and performance are poor, punishment should be punished in the continuation rules. If the application for the joint procurement office of the National Organization of Drugs is included in the "illegal list" or the province is identified as the dishonesty to varying degrees, it can take the disposal measures such as the election position, the proportion of the band, and the reduction of the supply area in accordance with the regulations. Suspension its qualifications to participate.

- END -